Tiger Brokers

CUTIA-B (02487) Sets 24 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend

Bulletin Express
Mar 12

Cutia Therapeutics (stock code: 02487) has scheduled a board meeting for 24 March 2026. Key agenda items include:

• Reviewing and approving the consolidated annual results for the year ended 31 December 2025.

• Considering the recommendation of a final dividend, if any.

• Addressing other routine corporate matters.

According to the announcement dated 12 March 2026, the current Board structure consists of:

• Executive Directors: Zhang Lele (Chief Executive Officer) and Huang Yuqing. • Non-Executive Directors: Dr. Chen Lian Yong, Dr. Xie Qin, Lu Minfang and Yang Yunxia. • Independent Non-Executive Directors: Chung Ming Kit, Zhang Zhisong and Ye Xiaoxiang.

The meeting’s outcome will be published following Board approval, providing investors with the company’s FY2025 financial performance and any dividend decision.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10